Low hepatitis c viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis c virus

Journal of Clinical Oncology

Volumn 31, Issue 6, 2013, Pages 766-773

  Shindoh, Junichi ^a   Hasegawa, Kiyoshi ^a   Matsuyama, Yutaka ^a   Inoue, Yosuke ^a   Ishizawa, Takeaki ^a   Aoki, Taku ^a   Sakamoto, Yoshihiro ^a   Sugawara, Yasuhiko ^a   Makuuchi, Masatoshi ^b   Kokudo, Norihiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPANESE RED CROSS MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; FEMALE; HEPATITIS; HEPATITIS C VIRAL LOAD; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE; VIRUS LOAD;

AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84875691816     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.3234     Document Type: Article

References (49)

1. Rahbari NN, Mehrabi A, Mollberg NM, et al: Hepatocellular carcinoma: Current management and perspectives for the future. Ann Surg 253:453-469, 2011
2. Belghtiti J, Panis Y, Farges O, et al: Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 214: 114-117, 1991
3. Grazi GL, Ercolani G, Pierangeli F, et al: Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg 234:71-78, 2001 (Pubitemid 32619337)
4. Imamura H, Matsuyama Y, Miyagawa Y, et al: Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg 86:1032-1038, 1999 (Pubitemid 29387069)
5. Kakazu T, Makuuchi M, Kawasaki S, et al: Repeat hepatic resection for recurrent hepatocellular carcinoma. Hepatogastroenterology 40:337-341, 1993 (Pubitemid 23258551)
6. Nakajima Y, Ko S, Kanamura T, et al: Repeat liver resection for hepatocellular carcinoma. J Am Coll Surg 192:339-344, 2001 (Pubitemid 32208875)
7. Poon RT, Fan ST, Lo CM, et al: Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: Implications for a strategy of salvage transplantation. Ann Surg 235:373-382, 2002 (Pubitemid 34183888)
8. Tsukuma H, Hiyama T, Tanaka S, et al: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797- 1801, 1993 (Pubitemid 23174709)
9. Kumada T, Nakano S, Takeda I, et al: Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 25:87- 92, 1997 (Pubitemid 27014990)
10. Yamanaka N, Tanaka T, Tanaka W, et al: Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma. Cancer 79:1509-1515, 1997 (Pubitemid 27154780)
11. Kubo S, Nishiguchi S, Hirohashi K, et al: Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 89:418-422, 2002 (Pubitemid 34595504)
12. Miyake Y, Takaki A, Iwasaki Y, et al: Metaanalysis: Interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 17:287-292, 2010
13. Singal AK, Freeman DH Jr., Anand BS: Metaanalysis: Interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 32:851-858, 2010
14. Kasahara A, Hayashi N, Mochizuki K, et al: Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy: The Osaka Liver Disease Study Group. J Viral Hepat 7:343-351, 2000
15. Yabuuchi I, Imai Y, Kawata S, et al: Long-term responders without eradication of hepatitis C virus after interferon therapy: Characterization of clinical profiles and incidence of hepatocellular carcinoma. Liver 20:290-295, 2000 (Pubitemid 30488000)
16. Hasegawa K, Kokudo N, Imamura H, et al: Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg 242:252-259, 2005 (Pubitemid 41033442)
17. Makuuchi M, Kosuge T, Takayama T, et al: Surgery for small liver cancers. Semin Surg Oncol 9:298-304, 1993 (Pubitemid 23216368)
18. Nakashima T, Kojiro M: Pathologic characteristics of hepatocellular carcinoma. Semin Liver Dis 6:259-266, 1986 (Pubitemid 17203554)
19. Liver Cancer Study Group of Japan: The General Rules for the Clinical and Pathological Study of Primary Liver Cancer (ed 5). Tokyo, Japan, Kanehara, 2008
20. Edmondson HA, Steiner PE: Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer 7:462-503, 1954
21. Desmet VJ, Gerber M, Hoofnagle JH, et al: Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 19:1513-1520, 1994 (Pubitemid 24166476)
22. Takayama T, Makuuchi M, Hirohashi S, et al: Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 28:1241-1246, 1998 (Pubitemid 28493833)
23. Combes B, Carithers RL Jr., Maddrey WC, et al: Biliary bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acid. Hepatology 29:1649-1654, 1999 (Pubitemid 29247034)
24. Yamamura Y, Kotaki H, Tanaka N, et al: The pharmacokinetics of glycyrrhizin and its restorative effect on hepatic function in patients with chronic hepatitis and in chronically carbon-tetrachlorideintoxicated rats. Biopharm Drug Dispos 18:717-725, 1997 (Pubitemid 27475187)
25. Fan ST, Ng IO, Poon RT, et al: Hepatectomy for hepatocellular carcinoma: The surgeon's role in long-term survival. Arch Surg 134:1124-1130, 1999 (Pubitemid 29473204)
26. Vauthey JN, Lauwers GY, Esnaola NF, et al: Simplified staging for hepatocellular carcinoma. J Clin Oncol 20:1527-1536, 2002 (Pubitemid 34260532)
27. Ikeda K, Marusawa H, Osaki Y, et al: Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: A prospective study. Ann Intern Med 146:649-656, 2007 (Pubitemid 351650520)
28. Fuster J, García-Valdecasas JC, Grande L, et al: Hepatocellular carcinoma and cirrhosis: Results of surgical treatment in a European series. Ann Surg 223:297-302, 1996 (Pubitemid 26086722)
29. Lee CS, Sheu JC, Wang M, et al: Long-term outcome after surgery for asymptomatic small hepatocellular carcinoma. Br J Surg 83:330-333, 1996 (Pubitemid 26083162)
30. Yamamoto J, Kosuge T, Takayama T, et al: Recurrence of hepatocellular carcinoma after surgery. Br J Surg 83:1219-1222, 1996 (Pubitemid 26290448)
31. Yamanaka N, Okamoto E, Toyosaka A, et al: Prognostic factors after hepatectomy for hepatocellular carcinomas: A univariate and multivariate analysis. Cancer 65:1104-1110, 1990 (Pubitemid 20072042)
32. Ikeda K, Arase Y, Saitoh S, et al: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor: A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32:228-232, 2000 (Pubitemid 30614654)
33. Shiratori Y, Shiina S, Teratani T, et al: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 138:299-306, 2003 (Pubitemid 36205926)
34. Suou T, Mitsuda A, Koda M, et al: Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: A pilot study. Hepatol Res 20:301-311, 2001 (Pubitemid 32573892)
35. Uenishi T, Kubo S, Hirohashi K, et al: Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res 24:404-412, 2002 (Pubitemid 36002130)
36. Uenishi T, Nishiguchi S, Tamori A, et al: Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. Hepatol Res 36:195-200, 2006 (Pubitemid 44575933)
37. Akamatsu M, Yoshida H, Shiina S, et al: Neither hepatitis C virus genotype nor virus load affects survival of patients with hepatocellular carcinoma. Eur J Gastroenterol Hepatol 16:459-466, 2004 (Pubitemid 38586473)
38. Uenishi T, Nishiguchi S, Tanaka S, et al: Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol 98:358-362, 2008
39. Kubo S, Hirohashi K, Tanaka H, et al: Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. World J Surg 24:1559-1565, 2000 (Pubitemid 32047287)
40. Miao RY, Zhao HT, Yang HY, et al: Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: A metaanalysis. World J Gastroenterol 16:2931-2942, 2010
41. Kogure T, Ueno Y, Fukushima K, et al: Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan. World J Gastroenterol 14:7225- 7230, 2008
42. Sezaki H, Suzuki F, Kawamura Y, et al: Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 54:1317- 1324, 2009
43. Hadziyannis SJ, Sette H Jr., Morgan TR, et al: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346-355, 2004
44. Tsubota A, Chayama K, Ikeda K, et al: Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 19:1088- 1094, 1994 (Pubitemid 24134229)
45. Kudo M, Sakaguchi Y, Chung H, et al: Longterm interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation: A matched case-control study. Oncology 72:132-138, 2007 (suppl 1) (Pubitemid 350256677)
46. Shimomura S, Ikeda N, Saito M, et al: Longterm interferon therapy after radiofrequency ablation is effective in treating patients with HCV-associated hepatocellular carcinoma. Hepatol Int 5:559-566, 2010
47. Hayashi N, Okanoue T, Tsubouchi H, et al: Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat 19:e134-e142, 2012
48. Poordad F, McCone J Jr., Bacon BR, et al: Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364:1195-1206, 2011
49. Zeuzem S, Andreone P, Pol S, et al: Telaprevir for retreatment of HCV infection. N Engl J Med 364:2417-2428, 2011